Please ensure Javascript is enabled for purposes of website accessibility

Sorrento Therapeutics Rejects Unsolicited Acquisition Offer

By Brian Orelli, PhD - Jan 27, 2020 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The offer undervalued the company, according to the board.

Sorrento Therapeutics' (SRNE 1.00%) board of directors unanimously rejected a proposal from a private-equity fund to acquire a majority or all of the company's shares for up to $7 per share. The board concluded that the offer "significantly undervalues the company and is not in the best interest of the shareholders."

Investors didn't come to the same conclusion. Shares of Sorrento closed down 9% to $3.88 on Monday on the news that the company was taking a pass on the buyout offer.

Man looking at stock charts clinching his fists

Image source: Getty Images.

Sorrento disclosed the bid earlier this month, which caused its shares to shoot as high as $5.09, although they retracted moderately after the company didn't jump to agree to the deal in the days that followed.

This isn't the first time Sorrento has given a pass to an unsolicited buyout bid. Last November, the board rejected a pair of offers to buy the company for between $3 and $5 per share.

The board said it plans to continue the development of its drug pipeline while pursuing strategic alliances and transactions. The biotech is developing immunotherapies for cancer and has a portfolio of pain-management drugs, including ZTlido, a next-generation lidocaine patch that is approved for a neuropathic pain condition called post-herpetic neuralgia.

Despite having a drug on the market, Sorrento lost $229 million in the first nine months of last year because it sold less than $12 million worth of product over that time frame.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.01 (1.00%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.